Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-IL22BP mRNA in Advanced Malignant Solid Tumors
NCT07583654Phase 1Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2026
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CP-IL22BP mRNA in solid tumor, sponsored by West China Hospital of Sichuan University. Primary endpoints: Dose-Limiting Toxicities at 9 weeks and Treatment discontinuation due to treatment-related adverse events at 9 weeks. Started Jul 2026; status: recruiting.
02
Drugs
CP-IL22BP mRNA
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07583654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583654.